

Korean startup Neurophet advances Alzheimer's Disease diagnosis in partnership with The Florey Strengthen Research

November 25, 2025 | News

Aiming to evaluate the utility of blood-based and other biomarkers for Alzheimer's disease diagnosis and management



South Korea-based Neurophet, an artificial intelligence (AI) solution startup for brain disorders diagnosis and treatment, is collaborating with the Florey Institute of Neuroscience and Mental Health (The Florey) in Australia on joint research using its brain neurodegeneration imaging analysis software, Neurophet AQUA.

This collaborative study, titled "Enhanced Dementia Diagnosis (EDD) in Australian Memory Clinics," aims to evaluate the utility of blood-based and other biomarkers in the diagnosis and management of Alzheimer's disease in a real-world clinical setting, including Neurophet's AQUA software. Through this initiative, both parties will accelerate their research collaboration to advance high-precision dementia diagnosis leveraging Neurophet AQUA.

Located in Melbourne, Australia, the Florey is the largest brain research center in the Southern Hemisphere, with over 500 researchers and staff. The Florey primarily focuses on studying neurodegenerative diseases that affect cognitive function, as well as depression, schizophrenia, and bipolar disorder.